171 related articles for article (PubMed ID: 38473326)
1. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
[TBL] [Abstract][Full Text] [Related]
2. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer.
Betella I; Fumagalli C; Rafaniello Raviele P; Schivardi G; De Vitis LA; Achilarre MT; Aloisi A; Garbi A; Maruccio M; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Colombo N; Multinu F
Int J Gynecol Cancer; 2022 Jun; ():. PubMed ID: 35732351
[TBL] [Abstract][Full Text] [Related]
3. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice.
de Biase D; Maloberti T; Corradini AG; Rosini F; Grillini M; Ruscelli M; Coluccelli S; Altimari A; Gruppioni E; Sanza V; Turchetti D; Galuppi A; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; De Leo A
Front Med (Lausanne); 2023; 10():1146499. PubMed ID: 37064027
[TBL] [Abstract][Full Text] [Related]
4. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Gynecol Oncol; 2023 Mar; 170():210-220. PubMed ID: 36709662
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract][Full Text] [Related]
8. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
9. Endometrial Cancer: Transitioning from Histology to Genomics.
Mitric C; Bernardini MQ
Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.
De Vitis LA; Schivardi G; Caruso G; Fumagalli C; Vacirca D; Achilarre MT; Aloisi A; Garbi A; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Bogani G; Colombo N; Multinu F; Betella I
Int J Gynecol Cancer; 2023 Dec; ():. PubMed ID: 38135437
[TBL] [Abstract][Full Text] [Related]
11. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
Knez J; Sobocan M; Belak U; Kavalar R; Zupin M; Büdefeld T; Potocnik U; Takac I
Radiol Oncol; 2021 Sep; 56(1):76-82. PubMed ID: 34529911
[TBL] [Abstract][Full Text] [Related]
13. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
14. Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.
Kang EY; Wiebe NJ; Aubrey C; Lee CH; Anglesio MS; Tilley D; Ghatage P; Nelson GS; Lee S; Köbel M
J Pathol Clin Res; 2022 Jan; 8(1):19-32. PubMed ID: 34596362
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population.
Ortoft G; Høgdall C; Hansen ES; Dueholm M
Int J Gynecol Cancer; 2021 Aug; 31(8):1116-1124. PubMed ID: 34112735
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
17. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
RAINBO Research Consortium
Int J Gynecol Cancer; 2022 Dec; 33(1):109-17. PubMed ID: 36600534
[TBL] [Abstract][Full Text] [Related]
18. Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion.
Jamieson A; Grube M; Leung S; Chiu D; Lum A; Kwon JS; Talhouk A; Gilks B; Kommoss S; McAlpine JN
Int J Gynecol Cancer; 2024 Apr; 34(4):544-549. PubMed ID: 38388178
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
20. Impact of the new molecular classification of endometrial cancer: A French cohort study.
Benichou J; Schwall C; Sastre-Garau X; Méreaux J; Miailhe G; Bendifallah S; Haddad B; Touboul C; Mitri-Frangieh R; Dabi Y
Gynecol Oncol; 2022 Sep; 166(3):515-521. PubMed ID: 35843738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
